What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge

1 hour ago 2

Jonathan Ponciano, The Motley Fool

Sat, May 23, 2026 astatine 5:40 PM CDT 4 min read

Superstring Capital Management chopped its involvement successful UroGen Pharma Ltd. (NASDAQ:URGN), selling 330,983 shares successful the archetypal 4th successful an estimated $6.64 cardinal commercialized based connected mean quarterly pricing, according to a May 14, 2026, SEC filing.

What happened

According to a filing with the Securities and Exchange Commission dated May 14, 2026, Superstring Capital Management reduced its presumption successful UroGen Pharma Ltd. by 330,983 shares. The estimated transaction worth is $6.64 million, based connected the mean closing terms for the 4th ended March 31, 2026. The quarter-end worth of the presumption fell by $9.86 million, reflecting some stock income and terms changes.

What other to cognize

This was a sale, with UroGen Pharma Ltd. representing 4.98% of the fund’s 13F reportable AUM aft the move
Top holdings aft the filing:
- NASDAQ: SMMT: $16.93 cardinal (12.1% of AUM)
- NASDAQ: IMVT: $8.88 cardinal (6.3% of AUM)
- NASDAQ: COGT: $8.67 cardinal (6.2% of AUM)
- NASDAQ: SVRA: $8.66 cardinal (6.2% of AUM)
- NASDAQ: URGN: $6.96 cardinal (5.0% of AUM)
As of Friday, shares of UroGen Pharma Ltd. were priced astatine $28.89, up implicit 600% successful the past twelvemonth and importantly outperforming the S&P 500, which is alternatively up astir 28% successful the aforesaid period.

Company Overview

Metric

Value

Price (as of Friday)	$28.89
Market Capitalization	$1.4 billion
Revenue (TTM)	$140.49 million
Net Income (TTM)	($133.22 million)

Company Snapshot

UroGen Pharma Ltd. develops and commercializes caller therapies for specialty cancers and urothelial diseases, with cardinal products including Jelmyto and the investigational UGN-102 and UGN-301.
The institution aims to grow its portfolio with pipeline candidates targeting non-muscle invasive bladder and precocious tract cancers.
UroGen leverages proprietary RTGel exertion and collaborates with starring pharmaceutical and probe institutions to beforehand its objective programs.

UroGen Pharma Ltd. is simply a biotechnology institution focused connected advancing innovative therapies for urothelial cancers, leveraging proprietary RTGel exertion and a robust objective pipeline. The institution pursues a strategy of addressing unmet aesculapian needs successful specialty oncology markets, with a peculiar accent connected non-muscle invasive bladder cancer. Its competitory borderline lies successful its differentiated transportation level and strategical collaborations with starring pharmaceutical and probe institutions.

What this transaction means for investors

This merchantability seems similar an illustration of profit-taking alternatively of a motion of mislaid conviction. Even aft trimming the position, UroGen remains 1 of Superstring's 5 largest holdings, accounting for astir 5% of reported assets. That's notable fixed the stock's much than 600% tally implicit the past year.

What's absorbing is that the merchantability comes arsenic UroGen continues to rack up objective and commercialized wins. Earlier this month, the institution reported that its recently approved bladder crab therapy ZUSDURI delivered a 64.5% probability of remaining disease-free astatine 3 years among patients who achieved a implicit response, with a median duration of effect inactive not reached.

Then conscionable 2 days later, UroGen announced encouraging Phase 3 information for UGN-103, a next-generation mentation of the therapy. The proceedings showed a 94.5% six-month duration of response, and absorption remains connected way to taxable an NDA successful the 3rd 4th of 2026.

For semipermanent investors, the cardinal question is whether UroGen tin crook objective momentum into a durable oncology franchise. With an approved merchandise already connected the market, a follow-on campaigner moving toward imaginable approval, and patent extortion for UGN-103 expected into 2041, the institution is opening to look much similar a level story.

Read Entire Article